8-K: Liminatus Pharma Faces Nasdaq Delisting Threat

Liminatus Pharma, Inc. received notices from Nasdaq for failing to meet minimum market value requirements, initiating a 180-day compliance period.

Summary

• Liminatus Pharma, Inc. (LIMN) received notices from Nasdaq on November 19, 2025, regarding non-compliance with listing rules.
• The company failed to maintain a minimum Market Value of Listed Securities (MVLS) of $50,000,000 for the last 30 consecutive business days.
• The company also failed to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000 for the last 30 consecutive business days.
• Additionally, the company does not meet the requirement of having total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years.
• Nasdaq has granted a 180-calendar-day compliance period, until May 18, 2026, to regain compliance.
• To regain compliance, the company's MVLS must close at $50,000,000 or more, or its MVPHS must close at $15,000,000 or more, for a minimum of ten consecutive business days.
• Failure to regain compliance could lead to delisting, with options to appeal or transfer to The Nasdaq Capital Market.

Sentiment

Score: 2

Explanation: The filing indicates severe non-compliance with Nasdaq listing rules across multiple financial metrics, including market value and revenue/asset thresholds. This poses a significant risk of delisting, reflecting very negative sentiment regarding the company's current financial health and market perception.

Negatives

• Failure to maintain a minimum Market Value of Listed Securities (MVLS) of $50,000,000.
• Failure to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000.
• Failure to meet the requirement of total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years.
• Risk of delisting from The Nasdaq Stock Market LLC if compliance is not regained within 180 days.

Risks

• There is no assurance that Nasdaq will accept the company's plan to regain compliance.
• There is no assurance that the company will regain compliance with Nasdaq listing rules during the compliance period or in the future.
• The company may not otherwise meet Nasdaq continued listing standards.
• Potential delisting of the company's securities from The Nasdaq Stock Market LLC.

Future Outlook

The company is working diligently to regain compliance with Nasdaq's listing rules. However, there is no assurance that the company will be able to regain compliance within the prescribed time period or meet Nasdaq's continued listing standards in the future.

Management Comments

• "The Company is working diligently to regain compliance with Nasdaqs listing rules."
• "However, there can be no assurance that the Company will be able to regain compliance within the prescribed time period."

Industry Context

This announcement reflects a common challenge for smaller or struggling public companies, particularly in the pharmaceutical sector, where market capitalization can fluctuate significantly based on clinical trial results, regulatory approvals, or funding news. Failure to maintain minimum market value often indicates a lack of investor confidence or significant operational challenges, which can be exacerbated in a competitive and capital-intensive industry like pharma.

Stakeholder Impact

• Shareholders: Face significant risk of delisting, which could lead to reduced liquidity, lower stock price, and potential transfer to an over-the-counter market, making shares harder to trade.
• Employees: Potential uncertainty regarding the company's future and stability, which could impact morale and retention.
• Creditors: May view the company as higher risk due to financial instability and potential delisting, potentially affecting credit terms or access to capital.

Next Steps

• Liminatus Pharma, Inc. must regain compliance with Nasdaq's MVLS Rule by having its MVLS close at $50,000,000 or more for a minimum of ten consecutive business days.
• Liminatus Pharma, Inc. must regain compliance with Nasdaq's MVPHS Rule by having its MVPHS close at $15,000,000 or more for a minimum of ten consecutive business days.
• The company has until May 18, 2026, to regain compliance.
• If compliance is not regained, the company may appeal a delisting determination to a Nasdaq Hearings Panel.
• Alternatively, the company may consider applying for a transfer to The Nasdaq Capital Market.

Key Dates

Recommendation

The company is facing imminent delisting from Nasdaq due to severe non-compliance with multiple listing rules, including critical market value and financial thresholds. This indicates significant underlying financial distress and a lack of investor confidence. While there's a compliance period, the explicit statement of "no assurance" of regaining compliance, coupled with the failure to meet asset/revenue requirements, suggests a high probability of further decline and potential loss of liquidity. Investors should consider exiting their positions to avoid further capital erosion.

Keywords

Liminatus Pharma, LIMN, Nasdaq, Delisting, Compliance, Market Value of Listed Securities, MVLS, Market Value of Publicly Held Shares, MVPHS, Listing Rules, SEC Filing, 8-K